Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: a PENDULUM analysis

Heart Vessels. 2022 Jun;37(6):942-953. doi: 10.1007/s00380-021-02003-w. Epub 2022 Jan 1.

Abstract

In patients undergoing percutaneous coronary intervention (PCI) with a stent, high on-treatment platelet reactivity may be associated with an increased risk of stroke. This post hoc analysis of the PENDULUM registry compared the risk of post-PCI stroke according to on-treatment P2Y12 reaction unit (PRU) values. Patients aged ≥ 20 years who underwent PCI were stratified by baseline PRU (at 12 and 48 h post-PCI) as either high (HPR, > 208), optimal (OPR, > 85 to ≤ 208), or low on-treatment platelet reactivity (LPR, ≤ 85). The incidences of non-fatal ischemic and non-ischemic stroke through to 12 months post-PCI were recorded. Almost all enrolled patients (6102/6267 [97.4%]) had a risk factor for ischemic stroke, and most were receiving dual antiplatelet therapy. Of the 5906 patients with PRU data (HPR, n = 2227; OPR, n = 3002; LPR, n = 677), 47 had a non-fatal stroke post-PCI (cumulative incidence: 0.68%, ischemic; 0.18%, non-ischemic stroke). Patients with a non-fatal ischemic stroke event had statistically significantly higher post-PCI PRU values versus those without an event (P = 0.037). The incidence of non-fatal non-ischemic stroke was not related to PRU value. When the patients were stratified by PRU ≤ 153 versus > 153 at 12-48 h post-PCI, a significant difference was observed in the cumulative incidence of non-fatal stroke at 12 months (P = 0.044). We found that patients with ischemic stroke tended to have higher PRU values at 12-48 h after PCI versus those without ischemic stroke.Clinical trial registration: UMIN000020332.

Keywords: Ischemic stroke; Platelet aggregation; Stents; Thrombosis.

MeSH terms

  • Blood Platelets
  • Humans
  • Ischemic Stroke*
  • Percutaneous Coronary Intervention* / adverse effects
  • Platelet Aggregation
  • Platelet Aggregation Inhibitors
  • Platelet Function Tests / adverse effects
  • Stroke* / epidemiology
  • Stroke* / etiology
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors